Cibus (NASDAQ:CBUS – Get Free Report) will likely be issuing its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $1.7040 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.
Cibus (NASDAQ:CBUS – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.06). The business had revenue of $1.68 million during the quarter, compared to analyst estimates of $1.61 million. Cibus had a negative return on equity of 200.87% and a negative net margin of 2,366.33%. On average, analysts expect Cibus to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Cibus Price Performance
NASDAQ CBUS opened at $1.90 on Wednesday. The stock’s 50 day simple moving average is $1.62 and its 200 day simple moving average is $1.96. Cibus has a one year low of $1.09 and a one year high of $4.19. The firm has a market cap of $145.03 million, a PE ratio of -0.96 and a beta of 1.61.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on CBUS
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in shares of Cibus during the second quarter worth approximately $207,000. Corient Private Wealth LLC acquired a new position in Cibus in the fourth quarter valued at approximately $145,000. Squarepoint Ops LLC acquired a new position in Cibus in the third quarter valued at approximately $62,000. AQR Capital Management LLC bought a new position in Cibus in the first quarter valued at approximately $73,000. Finally, Renaissance Technologies LLC grew its holdings in Cibus by 74.4% during the 4th quarter. Renaissance Technologies LLC now owns 69,400 shares of the company’s stock worth $121,000 after acquiring an additional 29,600 shares during the period. 33.81% of the stock is currently owned by institutional investors.
Cibus Company Profile
Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.
The company’s core business centers on trait development services and licensing partnerships.
Featured Stories
- Five stocks we like better than Cibus
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Cibus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus and related companies with MarketBeat.com's FREE daily email newsletter.
